CSL (CSLLY) Debt-to-Revenue : 0.78 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is CSL Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

CSL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,420 Mil. CSL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10,687 Mil. CSL's annualized Revenue for the quarter that ended in Dec. 2023 was $15,608 Mil. CSL's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.78.

CSL Debt-to-Revenue Historical Data

The historical data trend for CSL's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Debt-to-Revenue Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

Get a 7-Day Free Trial

0.55

0.66

0.57

0.92

0.93

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.48	1.03	0.87	0.98	0.78

Competitive Comparison of CSL's Debt-to-Revenue

For the Biotechnology subindustry, CSL's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CSL's Debt-to-Revenue falls into.

CSL Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CSL's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1055	+	11172)	/	13174
	=	0.93

CSL's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1420	+	10687)	/	15608
	=	0.78

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

CSL Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CSL's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

CMXHF:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.